1. Volume 93, Issue 1, Pages 231-244 (January 2018)
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin 
David Z.I. Cherney, Mark E. Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Søren S. Lund 
Kidney International 
Volume 93, Issue 1, Pages (January 2018)
DOI: /j.kint
Copyright © 2017 International Society of Nephrology Terms and Conditions

2. Figure 1
Adjusted mean difference with empagliflozin 25 mg versus placebo in change from baseline in (a) HbA1c, (b) weight, (c) systolic blood pressure (SBP) (from seated office measurements), and (d) diastolic blood pressure (DBP) (from seated office measurements) at week 24 with empagliflozin compared with placebo in the 24-week pooled Phase III study cohort in subgroups by estimated glomerular filtration rate (eGFR) at baseline. Analysis of covariance (last observation carried forward) in patients who received ≥1 dose of study medication and had a baseline HbA1c value. CI, confidence interval.
Kidney International  , DOI: ( /j.kint )
Copyright © 2017 International Society of Nephrology Terms and Conditions

3. Figure 2
Adjusted mean difference in change from baseline with empagliflozin 10 mg and empagliflozin 25 versus placebo in (a) HbA1c, (b) weight, (c) 24-hour systolic blood pressure (SBP) (from ambulatory blood pressure monitoring [ABPM]), and (d) 24-hour diastolic blood pressure (DBP) (ABPM) at week 12 with empagliflozin compared with placebo in the 12-week ABPM study cohort in subgroups by estimated glomerular filtration rate (eGFR) at baseline. Analysis of covariance (last observation carried forward) in patients who received ≥1 dose of study medication and had baseline HbA1c and mean 24-hour SBP values. CI, confidence interval.
Kidney International  , DOI: ( /j.kint )
Copyright © 2017 International Society of Nephrology Terms and Conditions

4. Figure 3
Estimated glomerular filtration rate (eGFR) according to Modification of Diet in Renal Disease (MDRD) equation over 24 weeks in pooled data from 24-week trials in subgroups by eGFR (MDRD) at baseline. Mixed-model repeated-measures analysis in randomized patients who received ≥1 dose of study drug. N represents the number of patients in the analysis set. ***P < ; **P < 0.01 for difference versus placebo in change from baseline.
Kidney International  , DOI: ( /j.kint )
Copyright © 2017 International Society of Nephrology Terms and Conditions

5. Figure 4
Estimated glomerular filtration rate (eGFR) according to Modification of Diet in Renal Disease (MDRD) equation over 12 weeks and at follow-up in the 12-week ambulatory blood pressure monitoring study cohort in subgroups by eGFR (MDRD) at baseline. Mixed-model repeated-measures analysis in patients who received ≥1 dose of the study drug. N represents the number of patients in the analysis set. ***P < ; **P < 0.01; *P < 0.05 for difference versus placebo in change from baseline.
Kidney International  , DOI: ( /j.kint )
Copyright © 2017 International Society of Nephrology Terms and Conditions